Longitudinal changes in whole-genome (WG) cell-free DNA (cfDNA) and methylation as a blood-based biomarker to identify early disease progression in advanced breast cancer

被引：0

作者：

Davis, Andrew A. ^{[1
]}

Chan, David ^{[2
]}

Oh, Michael S. ^{[1
]}

Lentz, Robert W. ^{[1
]}

Peterman, Neil ^{[3
,4
]}

Robertson, Alex ^{[3
,4
]}

Srivas, Rohith ^{[3
,4
]}

Shah, Abhik ^{[3
,4
]}

Lambert, Nicole ^{[3
,4
]}

Tezcan, Ayse ^{[3
,4
]}

Tezcan, Haluk ^{[3
,4
]}

Chae, Young Kwang ^{[1
]}

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[2] Canc Care Associates TMPN, Redondo Beach, CA USA

[3] Lexent Bio Inc, San Francisco, CA USA

[4] Lexent Bio Inc, San Diego, CA USA

来源：

CANCER RESEARCH | 2020年 / 80卷 / 04期

关键词：

D O I：

10.1158/1538-7445.SABCS19-P5-01-13

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P5-01-13

引用

页数：2

共 44 条

[41] Blood-based genomic profiling of cell-free DNA (cfDNA) to identify microsatellite instability (MSI-H), tumor mutational burden (TMB) and Wnt/B-Catenin pathway alterations in patients with gastrointestinal (GI) tract cancers.
Isaacs, James
Nixon, Andrew B.
Bolch, Emily
Quinn, Katie
Banks, Kimberly
Hanks, Brent Allen
Strickler, John H.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[42] Systematic review and meta-analysis of accuracy of tumor origin detection in blood cell-free DNA (cfDNA)-based multi-cancer early detection (MCED) assays in the general population.
Park, Joo Hee
Oh, Youjin
Chung, Liam Il-Young
Duan, Richard
Djunadi, Trie Arni
Yoon, Sung Mi
Shah, Zunairah
Jung, Chan Mi
Hong, Ilene
Kim, Leeseul
Choi, Horyun
Chae, Young Kwang
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[43] Efficacy and cell-free DNA whole methylome based biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple negative breast cancer: A prospective multi-center cohort study
Chen, X.
Xiu, M.
Kang, H.
Zhang, Y.
Li, Q.
Cheng, X.
Wang, J.
Lan, B.
Chen, S.
Xiao, M.
Qian, X.
Hua, B.
Xu, B.
Zhang, P.
ANNALS OF ONCOLOGY, 2024, 35 : S354 - S354
[44] Chancen und Risiken der blutbasierten molekularpathologischen Analytik zirkulierender Tumorzellen (CTC) und zellfreier DNA (cfDNA) in der personalisierten KrebstherapieEine Stellungnahme des Arbeitskreises „Liquid Biopsy“ der AG Molekularpathologie in der Deutschen Gesellschaft für Pathologie (DGP)Chances and risks of blood-based molecular pathological analysis of circulating tumor cells (CTC) and cell-free DNA (cfDNA) in personalized cancer therapyPositional paper from the study group on liquid biopsy of the working group for molecular pathology in the German Society of Pathology (DGP)
E. Dahl
A. Jung
J. Fassunke
M. Hummel
R. Penzel
W. Dietmaier
S. Laßmann
Der Pathologe, 2015, 36 (1): : 92 - 97

← 1 2 3 4 5 →